07:31 AM EST, 11/12/2024 (MT Newswires) -- Neumora Therapeutics ( NMRA ) reported a Q3 loss Tuesday of $0.45 per diluted share, narrower than the loss of $1.14 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.39.

The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended Sept. 30.

Neumora said it had $341.3 million in cash, cash equivalents and marketable securities at the end of the quarter, which it said would enable it to fund its operating plan into mid-2026.

Price: 13.58, Change: +0.04, Percent Change: +0.30